Clinical Trials

36 enrolled

Glioblastoma, Glioma

NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

71 enrolled

Epilepsy, Neuroblastoma

NCT07304154 2026-04-21

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

224 enrolled

Lymphoma, B-Cell

NCT06773091 2026-04-06

NKSOLID

76 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06834282 2026-03-27

CertainT-1

18 enrolled

Leukemia, Myeloid, Acute

NCT07492628 2026-03-25

DUET-UC-NK

42 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

54 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT06153251 2026-03-18

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

187 enrolled

Multiple Myeloma

NCT07480941 2026-03-18

DUAL-CAR-NK-GB

36 enrolled

Glioblastoma, Glioma

NCT06961786 2026-03-05

TUNINTIL-2

9 enrolled

Dermatologic

Melanoma

NCT03939026 2026-03-02

ALPHA

50 enrolled

Lymphoma, Lymphoma, Follicular, Recurrence

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

LymphoidMyeloidOther hematologic neoplasm

30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

NCT05170828 2026-02-24

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase 1 Withdrawn

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06220201 2026-02-10

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

120 enrolled

Multiple Sclerosis, Myasthenia Gravis

NCT04674813 2026-02-09

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

130 enrolled

Multiple Myeloma

NCT03666000 2026-02-02

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

135 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04230265 2026-01-22

Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

32 enrolled

Leukemia, Myeloid, Acute

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

31 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06241456 2025-12-09

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

351 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06285422 2025-11-28

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

6 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05878184 2025-10-02

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

16 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04696731 2025-09-25

TRAVERSE

120 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05722418 2025-09-25

CaMMouflage

50 enrolled

Multiple Myeloma

NCT05950334 2025-08-22

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

20 enrolled

Phase 1 Not yet recruiting

Lymphoma, B-Cell

NCT07105176 2025-08-19

HS-IT101 Injection for Advanced NSCLC

Thoracic

Advanced Non-Small Cell Lung Cancer

NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

LymphoidOther solid neoplasm

480 enrolled

Advanced Solid Tumor

NCT05653271 2025-08-11

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

42 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT07066397 2025-07-23

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04239092 2025-07-17

9-ING-41 in Pediatric Patients With Refractory Malignancies.

40 enrolled

Diffuse Intrinsic Pontine Glioma, Meningioma, Neoplasms, Neuroblastoma

NCT05881525 2025-07-16

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

18 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04789408 2025-07-11

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

15 enrolled 27 charts

Leukemia, Myeloid, Acute

NCT06415487 2025-07-01

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

30 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04735471 2025-06-18

GLEAN-1

34 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06128044 2025-06-11

AMpLify

Leukemia, Myeloid, Acute

NCT02303821 2025-06-04

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

141 enrolled 37 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03994705 2025-05-15

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

20 enrolled 12 charts

Multiple Myeloma

NCT05949125 2025-05-14

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

80 enrolled

Leukemia, Myeloid, Acute

NCT06699771 2025-04-30

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

48 enrolled

Lymphoma, T-Cell

NCT05665062 2025-04-06

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

36 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06251180 2025-03-25

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

112 enrolled

Lymphoma, B-Cell

NCT04637763 2025-03-24

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

72 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02876510 2025-02-04

ACTolog

GastrointestinalGynecologicHead & NeckThoracic

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT06341647 2025-01-24

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Phase 1 Withdrawn

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

111 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

MyeloidOther hematologic neoplasm

61 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04319757 2024-12-05

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors